查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球语音生物标誌物市场:市场规模、份额、趋势分析、机会、预测-按类型、适应症、神经系统疾病、最终用户、地区 (2019-2029)
市场调查报告书
商品编码
1227602

全球语音生物标誌物市场:市场规模、份额、趋势分析、机会、预测-按类型、适应症、神经系统疾病、最终用户、地区 (2019-2029)

Vocal Biomarkers Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type, By Indications, By Neurological Disorders, By End User, By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球语音生物标誌物市场规模将在 2022 年达到 30.1 亿美元，到 2029 年达到 62.2 亿美元，在 2023-2029 年的预测期内以 11% 的复合年增长率增长。

在帕金森病和其他疾病患病率上升、对诊断各种疾病的微创治疗需求激增以及心血管和精神疾病发病率上升的推动下，全球市场正在蓬勃发展。

本报告考察了全球语音生物标誌物市场，并提供了市场洞察、市场概况、区域市场分析、竞争格局、公司概况等资讯。

目次

第 1 章研究框架

第 2 章执行摘要

第 3 章全球语音生物标誌物市场洞察

  • 工业价值链分析
  • DROC 分析
    • 促进因素
      • 帕金森病和其他疾病的患病率上升
      • 对用于诊断各种疾病的微创治疗的需求激增
      • 心血管和精神疾病的发病率上升
    • 抑制因素
      • 语音生物标誌物的错误和不准确
      • 高技术成本
    • 机会
      • 增加语音生物标誌物研究调查
      • 语音生物标誌物的成功临床试验
    • 任务
  • 技术进步/最新发展
  • 监管框架
  • 波特的五力分析
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争激烈程度

第 4 章全球语音生物标誌物市场概述

  • 2019-2029 年市场规模和预测
    • 按金额（十亿美元）
  • 市场份额/预测
    • 按类型
      • 频率
      • 振幅
      • 错误率
      • 音频上升/下降时间
      • 工作时间
      • 声音震颤
      • 推介
    • 根据指示
      • 抑郁症
      • 注意力不集中
      • 破坏性行为障碍
      • 其他
    • 神经系统疾病
      • 帕金森病
      • 阿尔茨海默病
      • 亨廷顿舞蹈症
      • 呼吸和心血管疾病
      • 创伤性脑损伤
    • 最终用户
      • 医院和诊所
      • 学术研究所
      • 其他
    • 按地区
      • 北美
      • 欧洲
      • 亚太地区
      • 拉丁美洲
      • 中东和非洲

第 5 章北美语音生物标记市场

  • 2019-2029 年市场规模和预测
    • 按金额（十亿美元）
  • 市场份额/预测
    • 按类型
    • 根据指示
    • 神经系统疾病
    • 最终用户
    • 按国家
      • 美国
      • 加拿大

第 6 章欧洲之声生物标誌物市场

  • 2019-2029 年市场规模和预测
    • 按金额（十亿美元）
  • 市场份额/预测
    • 按类型
    • 根据指示
    • 神经系统疾病
    • 最终用户
    • 按国家
      • 德国
      • 英国
      • 意大利
      • 法国
      • 西班牙
      • 荷兰
      • 其他欧洲

第 7 章亚太语音生物标誌物市场

  • 2019-2029 年市场规模和预测
    • 按金额（十亿美元）
  • 市场份额/预测
    • 按类型
    • 根据指示
    • 神经系统疾病
    • 最终用户
    • 按国家
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳大利亚和新西兰
      • 印度尼西亚
      • 马来西亚
      • 新加坡
      • 菲律宾
      • 越南
      • 亚太其他地区

第 8 章拉丁美洲语音生物标誌物市场

  • 2019-2029 年市场规模和预测
    • 按金额（十亿美元）
  • 市场份额/预测
    • 按类型
    • 根据指示
    • 神经系统疾病
    • 最终用户
    • 按国家
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 哥伦比亚
      • 其他拉丁美洲

第 9 章中东和非洲语音生物标誌物市场

  • 2019-2029 年市场规模和预测
    • 按金额（十亿美元）
  • 市场份额/预测
    • 按类型
    • 根据指示
    • 神经系统疾病
    • 最终用户
    • 按国家
      • 沙特阿拉伯
      • 阿拉伯联合酋长国
      • 卡塔尔
      • 科威特
      • 南非
      • 尼日利亚
      • 阿尔及利亚
      • 其他中东和非洲地区

第 10 章竞争格局

  • 主要公司和产品列表
  • 2022 年全球语音生物标誌物公司的市场份额分析
  • 竞争基准：按运营参数
  • 重大战略发展（合併、收购、合作等）

第 11 章 COVID-19 对全球语音生物标誌物市场的影响

第 12 章公司概况（公司概况、财务矩阵、竞争格局、主要人员、主要竞争对手、联繫地址、战略前景、SWOT分析）

  • Sonde Health
  • Beyond Verbal
  • IBM Corporation
  • Cogito Corporation
  • Boston Technology Corporation
  • Microtest Health
  • 其他有影响力的公司

第 13 章关键战略建议

第 14 章研究方法论

简介目录
Product Code: BWC20123

Global Vocal Biomarker Market Size More Than Doubles Cross USD 6.2 Billion by 2029.

Global vocal biomarker market is flourishing because of rising prevalence of Parkinson's and other diseases, a surging demand for minimally invasive treatments to diagnose different illnesses, and the increasing incidence of cardiovascular and mental disorders.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global vocal biomarker market size at USD 3.01 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global vocal biomarker market size to grow at a significant CAGR of 11% reaching a value of USD 6.22 billion by 2029. Major growth drivers for global vocal biomarker market include increasing incidence of neurological, psychological, and other speech-related diseases, including attention deficit, Parkinson's disease, depression, and cardiovascular diseases. These disorders necessitate less invasive tests for treatment, resulting in an increase in demand for vocal biomarkers. Vocal biomarkers are mainly used to detect illnesses using non-invasive speech features. Its use is based on the premise that severe illnesses have an effect on motor control and so change speech output by changing speech features. Vocal biomarkers are increasingly being employed to detect neurological disorders. Alzheimer's, schizophrenia, and Parkinson's disease typically manifest at a later stage of the disease, limiting the doctor's capacity to implement harsh measures. This allows pharmaceutical companies to create and test vocal biomarkers to aid in the early detection of such illnesses. Aside from healthcare, voice biomarkers have uses in lie detection. They are thought to be useful in defense and security organizations while questioning a criminal. Therefore, such factors are expected to fuel the expansion of overall market during period in analysis. However, errors and inaccuracy of vocal biomarkers is expected to hinder market growth.

Global Vocal Biomarker Market - Overview:

In the event of serious illnesses, early disease identification might mean the difference between a person's life and death. The development of new techniques that assist physicians and patients in diagnosing illnesses early has decreased death rates. Vocal biomarkers are one such advancement in the world of medicine. A human body's symptom or medical condition can be a biomarker. It is the pattern of speech in the case of vocal biomarkers. The vocal biomarkers market growth has been expanding steadily over the past several years and is predicted to have an extraordinary development in the years to come. Vocal biomarkers offer several benefits that increase their market demand. The requirement for early illness diagnosis, particularly from developed and developing nations, is one of the most crucial elements. Additionally, it is now among the most economical methods for illness diagnosis.

Global Vocal Biomarker Market - By Type:

By type, the global vocal biomarker market is segmented into amplitude, error rate, frequency, vocal rise or fall duration, voice tremor, pitch, and phonation time. The voice tremor segment is expected to hold the highest market share. It is a neurological condition that results in the uncontrollable movement of the vocal cords and throat muscles. The market dynamics will also be further influenced by the rising prevalence of neurological illnesses and the developing use of vocal tremors in neurological disorders.

Impact of COVID-19 on Global Vocal Biomarkers Market

The COVID-19 had a detrimental impact on the voice biomarkers industry globally. The pandemic has hampered the production and supply of voice biomarkers worldwide for various illnesses in these major economies. However, COVID-19 therapy now includes employs voice biomarkers. For instance, in December 2021, Vocalis Health developed a software program called Vocalis Check that evaluates a person's voice if they have an uncertain COVID-19 status. Due to the current worldwide pandemic, these developments are expected to significantly accelerate market growth and present possibilities for industry participants. The pandemic has led to an increase in the use of telemedicine and remote monitoring technologies, and vocal biomarkers may be able to play a role in these systems. For example, vocal biomarkers could potentially be used to assess the health status of patients remotely and to provide information to healthcare providers about changes in a patient's condition.

Competitive Landscape:

Major players operating in global vocal biomarker market include: Sonde Health, Beyond Verbal, IBM Corporation, Cogito Corporation, Boston Technology Corporation, and Microtest Health. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the Global Vocal Biomarker Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Vocal Biomarker Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Vocal Biomarker Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing Prevalence of Parkinson's Disease and Other Diseases
      • 3.2.1.2. Increasing Need for Minimally Invasive Treatments to Diagnose Different Illnesses
      • 3.2.1.3. Rising Incidence of Cardiovascular and Mental Disorders
    • 3.2.2. Restraints
      • 3.2.2.1. Errors and Inaccuracy of Vocal Biomarkers
      • 3.2.2.2. High Cost of Techniques
    • 3.2.3. Opportunities
      • 3.2.3.1. Increasing The Research Study of Vocal Biomarkers
      • 3.2.3.2. Successful Completion of Clinical Investigations of Voice Biomarker
    • 3.2.4. Challenges
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Vocal Biomarker Market Overview

  • 4.1. Market Size & Forecast by Value, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Frequency
      • 4.2.1.2. Amplitude
      • 4.2.1.3. Error Rate
      • 4.2.1.4. Vocal Rise or Fall Time
      • 4.2.1.5. Phonation Time
      • 4.2.1.6. Voice Tremor
      • 4.2.1.7. Pitch
    • 4.2.2. By Indication
      • 4.2.2.1. Depression
      • 4.2.2.2. Attention Deficit
      • 4.2.2.3. Disruptive Behavior Disorders
      • 4.2.2.4. Others
    • 4.2.3. By Neurological Disorders
      • 4.2.3.1. Parkinson's Disease
      • 4.2.3.2. Alzheimer's Disease
      • 4.2.3.3. Huntington's Disease
      • 4.2.3.4. Respiratory and Cardiovascular Disorders
      • 4.2.3.5. Traumatic Brain Injury
    • 4.2.4. By End User
      • 4.2.4.1. Hospitals and Clinics
      • 4.2.4.2. Academic and Research
      • 4.2.4.3. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific
      • 4.2.5.4. Latin America
      • 4.2.5.5. Middle East and Africa

5. North America Vocal Biomarker Market

  • 5.1. Market Size & Forecast by Value, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Indication
    • 5.2.3. By Neurological Disorders
    • 5.2.4. By End User
    • 5.2.5. By Country
      • 5.2.5.1. US
      • 5.2.5.1.1. By Type
      • 5.2.5.1.2. By Indication
      • 5.2.5.1.3. By Neurological Disorders
      • 5.2.5.1.4. By End User
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Type
      • 5.2.5.2.2. By Indication
      • 5.2.5.2.3. By Neurological Disorders
      • 5.2.5.2.4. By End User

6. Europe Vocal Biomarker Market

  • 6.1. Market Size & Forecast by Value, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Indication
    • 6.2.3. By Neurological Disorders
    • 6.2.4. By End User
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Type
      • 6.2.5.1.2. By Indication
      • 6.2.5.1.3. By Neurological Disorders
      • 6.2.5.1.4. By End User
      • 6.2.5.2. UK
      • 6.2.5.2.1. By Type
      • 6.2.5.2.2. By Indication
      • 6.2.5.2.3. By Neurological Disorders
      • 6.2.5.2.4. By End User
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Type
      • 6.2.5.3.2. By Indication
      • 6.2.5.3.3. By Neurological Disorders
      • 6.2.5.3.4. By End User
      • 6.2.5.4. France
      • 6.2.5.4.1. By Type
      • 6.2.5.4.2. By Indication
      • 6.2.5.4.3. By Neurological Disorders
      • 6.2.5.4.4. By End User
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Type
      • 6.2.5.5.2. By Indication
      • 6.2.5.5.3. By Neurological Disorders
      • 6.2.5.5.4. By End User
      • 6.2.5.6. The Netherlands
      • 6.2.5.6.1. By Type
      • 6.2.5.6.2. By Indication
      • 6.2.5.6.3. By Neurological Disorders
      • 6.2.5.6.4. By End User
      • 6.2.5.7. Rest of Europe
      • 6.2.5.7.1. By Type
      • 6.2.5.7.2. By Indication
      • 6.2.5.7.3. By Neurological Disorders
      • 6.2.5.7.4. By End User

7. Asia-Pacific Vocal Biomarker Market

  • 7.1. Market Size & Forecast by Value, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Indication
    • 7.2.3. By Neurological Disorders
    • 7.2.4. By End User
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Type
      • 7.2.5.1.2. By Indication
      • 7.2.5.1.3. By Neurological Disorders
      • 7.2.5.1.4. By End User
      • 7.2.5.2. India
      • 7.2.5.2.1. By Type
      • 7.2.5.2.2. By Indication
      • 7.2.5.2.3. By Neurological Disorders
      • 7.2.5.2.4. By End User
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Type
      • 7.2.5.3.2. By Indication
      • 7.2.5.3.3. By Neurological Disorders
      • 7.2.5.3.4. By End User
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Type
      • 7.2.5.4.2. By Indication
      • 7.2.5.4.3. By Neurological Disorders
      • 7.2.5.4.4. By End User
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Type
      • 7.2.5.5.2. By Indication
      • 7.2.5.5.3. By Neurological Disorders
      • 7.2.5.5.4. By End User
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Type
      • 7.2.5.6.2. By Indication
      • 7.2.5.6.3. By Neurological Disorders
      • 7.2.5.6.4. By End User
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Type
      • 7.2.5.7.2. By Indication
      • 7.2.5.7.3. By Neurological Disorders
      • 7.2.5.7.4. By End User
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Type
      • 7.2.5.8.2. By Indication
      • 7.2.5.8.3. By Neurological Disorders
      • 7.2.5.8.4. By End User
      • 7.2.5.9. Philippines
      • 7.2.5.9.1. By Type
      • 7.2.5.9.2. By Indication
      • 7.2.5.9.3. By Neurological Disorders
      • 7.2.5.9.4. By End User
      • 7.2.5.10. Vietnam
      • 7.2.5.10.1. By Type
      • 7.2.5.10.2. By Indication
      • 7.2.5.10.3. By Neurological Disorders
      • 7.2.5.10.4. By End User
      • 7.2.5.11. Rest of Asia Pacific
      • 7.2.5.11.1. By Type
      • 7.2.5.11.2. By Indication
      • 7.2.5.11.3. By Neurological Disorders
      • 7.2.5.11.4. By End User

8. Latin America Vocal Biomarker Market

  • 8.1. Market Size & Forecast by Value, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Indication
    • 8.2.3. By Neurological Disorders
    • 8.2.4. By End User
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Type
      • 8.2.5.1.2. By Indication
      • 8.2.5.1.3. By Neurological Disorders
      • 8.2.5.1.4. By End User
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Type
      • 8.2.5.2.2. By Indication
      • 8.2.5.2.3. By Neurological Disorders
      • 8.2.5.2.4. By End User
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Type
      • 8.2.5.3.2. By Indication
      • 8.2.5.3.3. By Neurological Disorders
      • 8.2.5.3.4. By End User
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Type
      • 8.2.5.4.2. By Indication
      • 8.2.5.4.3. By Neurological Disorders
      • 8.2.5.4.4. By End User
      • 8.2.5.5. Colombia
      • 8.2.5.5.1. By Type
      • 8.2.5.5.2. By Indication
      • 8.2.5.5.3. By Neurological Disorders
      • 8.2.5.5.4. By End User
      • 8.2.5.6. Rest of LATAM
      • 8.2.5.6.1. By Type
      • 8.2.5.6.2. By Indication
      • 8.2.5.6.3. By Neurological Disorders
      • 8.2.5.6.4. By End User

9. Middle East & Africa Vocal Biomarker Market

  • 9.1. Market Size & Forecast by Value, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Indication
    • 9.2.3. By Neurological Disorders
    • 9.2.4. By End User
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Type
      • 9.2.5.1.2. By Indication
      • 9.2.5.1.3. By Neurological Disorders
      • 9.2.5.1.4. By End User
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Type
      • 9.2.5.2.2. By Indication
      • 9.2.5.2.3. By Neurological Disorders
      • 9.2.5.2.4. By End User
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Type
      • 9.2.5.3.2. By Indication
      • 9.2.5.3.3. By Neurological Disorders
      • 9.2.5.3.4. By End User
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Type
      • 9.2.5.4.2. By Indication
      • 9.2.5.4.3. By Neurological Disorders
      • 9.2.5.4.4. By End User
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Type
      • 9.2.5.5.2. By Indication
      • 9.2.5.5.3. By Neurological Disorders
      • 9.2.5.5.4. By End User
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Type
      • 9.2.5.6.2. By Indication
      • 9.2.5.6.3. By Neurological Disorders
      • 9.2.5.6.4. By End User
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Type
      • 9.2.5.7.2. By Indication
      • 9.2.5.7.3. By Neurological Disorders
      • 9.2.5.7.4. By End User
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Type
      • 9.2.5.8.2. By Indication
      • 9.2.5.8.3. By Neurological Disorders
      • 9.2.5.8.4. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Vocal Biomarker Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, and others)

11. Impact of Covid-19 on Global Vocal Biomarker Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 12.1. Sonde Health
  • 12.2. Beyond Verbal
  • 12.3. IBM Corporation
  • 12.4. Cogito Corporation
  • 12.5. Boston Technology Corporation
  • 12.6. Microtest Health
  • 12.7. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations